Advertisement
Review Article| Volume 18, ISSUE 2, P243-250, April 2023

Gastro-Entero-Pancreatic Tumors

FDG Positron Emission Tomography/Computed Tomography
  • Wajahat Khatri
    Affiliations
    Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 North Caroline Street, JHOC 3, Baltimore, MD 21287, USA
    Search for articles by this author
  • Ergi Spiro
    Affiliations
    Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 North Caroline Street, JHOC 3, Baltimore, MD 21287, USA
    Search for articles by this author
  • Amanda Henderson
    Affiliations
    Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 North Caroline Street, JHOC 3, Baltimore, MD 21287, USA
    Search for articles by this author
  • Steven P. Rowe
    Affiliations
    Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 North Caroline Street, JHOC 3, Baltimore, MD 21287, USA
    Search for articles by this author
  • Lilja B. Solnes
    Correspondence
    Corresponding author.
    Affiliations
    Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 North Caroline Street, JHOC 3, Baltimore, MD 21287, USA
    Search for articles by this author
Published:January 25, 2023DOI:https://doi.org/10.1016/j.cpet.2022.11.007
Gastro-Entero-Pancreatic Tumors
Previous ArticleParagangliomas and Pheochromocytomas
Next ArticleNeuroendocrine Neoplasms

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to PET Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Squires M.H.
        • Volkan Adsay N.
        • Schuster D.M.
        • et al.
        Octreoscan versus FDG-PET for neuroendocrine tumor staging: a biological approach.
        Ann Surg Oncol. 2015; 22: 2295-2301
        View in Article
        • Alevroudis E.
        • Spei M.E.
        • Chatziioannou S.N.
        • et al.
        Clinical utility of 18F-FDG pet in neuroendocrine tumors prior to peptide receptor radionuclide therapy: a systematic review and meta-analysis.
        Cancers. 2021; 13: 1813
        View in Article
        • Bösch F.
        • Ghadimi M.
        • Angele M.K.
        Personalisierte resektionsverfahren bei neuroendokrinen neoplasien des pankreas [Personalised surgical therapy for neuroendocrine neoplasia of the pancreas].
        Zentralblatt für Chirurgie. 2022; 147: 264-269
        View in Article
        • Tsoli M.
        • Chatzellis E.
        • Koumarianou A.
        • et al.
        Current best practice in the management of neuroendocrine tumors.
        Ther Adv Endocrinol Metab. 2018; 10 (204201881880469)
        View in Article
        • Dasari A.
        • Shen C.
        • Halperin D.
        • et al.
        Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States.
        JAMA Oncol. 2017; 3: 1335-1342
        View in Article
        • Chen S.H.
        • Chang Y.C.
        • Hwang T.L.
        • et al.
        68Ga-DOTATOC and 18F-FDG PET/CT for identifying the primary lesions of suspected and metastatic neuroendocrine tumors: a prospective study in Taiwan.
        J Formos Med Assoc. 2018; 117: 480-487
        View in Article
        • Lussey-Lepoutre C.
        • Hindié E.
        • Montravers F.
        • et al.
        The current role of 18F-FDOPA PET for neuroendocrine tumor imaging.
        Médecine Nucléaire. 2016; 40: 20-30
        View in Article
        • Grey N.
        • Silosky M.
        • Lieu C.H.
        • et al.
        Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors.
        World J Gastroenterol. 2022; 28: 1768-1780
        View in Article
        • Hofman M.S.
        Principles and application of molecular imaging for personalized medicine and guiding interventions in neuroendocrine tumors.
        Diagn Ther Nucl Med Neuroendocrine Tumors. 2016; : 219-238https://doi.org/10.1007/978-3-319-46038-3_10
        View in Article
        • Panagiotidis E.
        • Alshammari A.
        • Michopoulou S.
        • et al.
        Comparison of the impact of 68 Ga-DOTATATE and 18F-FDG PET/CT on clinical management in patients with neuroendocrine tumors.
        J Nucl Med. 2016; 58: 91-96
        View in Article
        • Kayani I.
        • Bomanji J.B.
        • Groves A.
        • et al.
        Functional imaging of neuroendocrine tumors with combined PET/CT using 68 Ga-DOTATATE (DOTA-dphe1,tyr3-octreotate) and 18F-FDG.
        Cancer. 2008; 112: 2447-2455
        View in Article
        • Binderup T.
        • Knigge U.
        • Loft A.
        • et al.
        18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors.
        Clin Cancer Res. 2010; 16: 978-985
        View in Article
        • Papadakis G.Z.
        • Karantanas A.H.
        • Marias K.
        • et al.
        Current status and future prospects of PET-imaging applications in patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs).
        Eur J Radiol. 2021; 143: 109932
        View in Article
        • Hicks R.J.
        • Kwekkeboom D.J.
        • Krenning E.
        • et al.
        ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: peptide receptor radionuclide therapy with radiolabelled somatostatin analogues.
        Neuroendocrinology. 2017; 105: 295-309
        View in Article
        • Strosberg J.
        • El-Haddad G.
        • Wolin E.
        • et al.
        Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors.
        N Engl J Med. 2017; 376: 125-135
        View in Article
        • Strosberg J.R.
        • Caplin M.E.
        • Kunz P.L.
        • et al.
        177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.
        Lancet Oncol. 2021; 22: 1752-1763
        View in Article
        • Kayani I.
        • Conry B.G.
        • Groves A.M.
        • et al.
        A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors.
        J Nucl Med. 2009; 50: 1927-1932
        View in Article
        • Nilica B.
        • Waitz D.
        • Stevanovic V.
        • et al.
        Direct comparison of 68Ga-DOTA-TOC and 18F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
        Eur J Nucl Med Mol Imaging. 2016; 43: 1585-1592
        View in Article
        • Chan D.L.
        • Pavlakis N.
        • Schembri G.P.
        • et al.
        Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance.
        Theranostics. 2017; 7: 1149-1158
        View in Article
        • Werner R.A.
        • Solnes L.B.
        • Javadi M.S.
        • et al.
        SSTR-RADS version 1.0 as a reporting system for SSTR PET imaging and selection of potential PRRT candidates: a proposed standardization framework.
        J Nucl Med. 2018; 59: 1085-1091
        View in Article
        • Severi S.
        • Nanni O.
        • Bodei L.
        • et al.
        Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours.
        Eur J Nucl Med Mol Imaging. 2013; 40: 881-888
        View in Article
        • Weich A.
        • Werner R.A.
        • Serfling S.E.
        • et al.
        Rechallenge with additional doses of 177Lu-DOTATOC after failure of maintenance therapy with cold somatostatin analogs.
        Clin Nucl Med. 2022; 47: 719-720
        View in Article
        • Kim Y.I.
        Salvage peptide receptor radionuclide therapy in patients with progressive neuroendocrine tumors: systematic review and meta-analysis.
        Nucl Med Commun. 2020; 42: 451-458
        View in Article
        • Rodrigues M.
        • Winkler K.K.
        • Svirydenka H.
        • et al.
        Long-term survival and value of 18F-FDG PET/CT in patients with gastroenteropancreatic neuroendocrine tumors treated with second peptide receptor radionuclide therapy course with 177Lu-DOTATATE.
        Life. 2021; 11: 198
        View in Article
        • Lapa C.
        • Werner R.A.
        • Herrmann K.
        Visualization of tumor heterogeneity in neuroendocrine tumors by positron emission tomography.
        Endocrine. 2016; 51: 556-557
        View in Article

      Article info

      Publication history

      Published online: January 25, 2023

      Identification

      DOI: https://doi.org/10.1016/j.cpet.2022.11.007

      Copyright

      © 2022 Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX